Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/01/24
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology ConferenceGlobeNewsWire • 07/30/24
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid LeukGlobeNewsWire • 06/14/24
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewsWire • 06/10/24
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk MyGlobeNewsWire • 06/06/24
After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)Zacks Investment Research • 05/21/24
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the EGlobeNewsWire • 05/14/24
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?Zacks Investment Research • 05/07/24
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/02/24
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/02/24
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewsWire • 04/09/24
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/24
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.GlobeNewsWire • 03/04/24
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/29/24
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsPRNewsWire • 02/14/24
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory DiseasesGlobeNewsWire • 02/13/24
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024GlobeNewsWire • 01/08/24
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsGlobeNewsWire • 12/21/23